Anavex Life Sciences Corp AVXL

Healthcare Biotechnology

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

NDAQ:AVXL - Post by User

Anavex Life Sciences Corp

<< Previous

Bullboard Posts

Next >>

Post by R_J_on Oct 31, 2020 9:58pm

201 Views

Post# 31819459

End of Month - October 2020

End of the Month (EOM) report for October 2020 for Anavex Life Sciences Corp.
-
AVXL closed on 10/30/2020 at US$5.90
AVXL closed on 09/30/2020 at US$4.55
-
This is a 27.9%, a US$1.35, Gain for October.
-
S&P 500 Index, @ 3269.9 lost 2.8% in October. [4.5% above its MA(200) @ 3129.4]
-
Two Hundred Day Moving Average [MA(200)] stuff.
AVXL's MA(200) ended October at $4.03
AVXL is now 46.6% above its MA(200).
-
News Releases on the AVXL Website in October
-
Use this link to see and read the all of October’s News Releases.
-
[url= https://www.anavex.com/2020/10/] https://www.anavex.com/2020/10/[/url]
-
Who is the Big Cheese at AVXL?
Christopher U. Missling, PhD, President & CEO
-
RJ

<< Previous

Bullboard Posts

Next >>

Canopy Growth prepares for U.S. expansion with new acquisitions